We are live on ! Find out more
EW icon

Edwards Lifesciences

556 hedge funds and large institutions have $11.7B invested in Edwards Lifesciences in 2014 Q4 according to their latest regulatory filings, with 97 funds opening new positions, 193 increasing their positions, 182 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more first-time investments, than exits

New positions opened: 97 | Existing positions closed: 31

50% more funds holding in top 10

Funds holding in top 10: 1015 (+5)

12% more funds holding

Funds holding: 496556 (+60)

6% more repeat investments, than reductions

Existing positions increased: 193 | Existing positions reduced: 182

5% less capital invested

Capital invested by funds: $12.4B → $11.7B (-$651M)

7.78% less ownership

Funds ownership: 523.44%515.66% (-7.8%)

15% less call options, than puts

Call options by funds: $44.3M | Put options by funds: $52.1M

Holders
556
Holders Change
+60
Holders Change %
+12.1%
% of All Funds
14.83%
Holding in Top 10
15
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+50%
% of All Funds
0.4%
New
97
Increased
193
Reduced
182
Closed
31
Calls
$44.3M
Puts
$52.1M
Net Calls
-$7.8M
Net Calls Change
-$17.2M
Name Holding Trade Value Shares
Change
Change in
Stake
PI
101
Putnam Investments
Massachusetts
$17.5M +$15.5M +770,958 +1,436%
Credit Agricole
102
Credit Agricole
France
$17.5M +$9.66M +480,882 +147%
RFS
103
Rockefeller Financial Services
New York
$17.4M +$347K +17,262 +2%
Boston Partners
104
Boston Partners
Massachusetts
$17.4M -$96.4K -4,800 -0.6%
PAM
105
Panagora Asset Management
Massachusetts
$16.7M +$7.97M +396,870 +102%
QI
106
QS Investors
New York
$16.3M +$7.68M +382,380 +99%
Grantham, Mayo, Van Otterloo & Co (GMO)
107
Grantham, Mayo, Van Otterloo & Co (GMO)
Massachusetts
$16.2M -$2.8M -139,176 -15%
Comerica Bank
108
Comerica Bank
Texas
$16.1M +$7.73M +384,864 +103%
HCM
109
Highbridge Capital Management
New York
$16.1M -$34.4M -1,710,780 -69%
BIM
110
Bogle Investment Management
Massachusetts
$16M -$5.91K -294 -0%
ARC
111
Absolute Return Capital
Massachusetts
$15.9M -$18.6M -923,832 -55%
SFM
112
Systematic Financial Management
New Jersey
$15.4M -$721K -35,892 -5%
State of Wisconsin Investment Board
113
State of Wisconsin Investment Board
Wisconsin
$15.3M +$567K +28,200 +4%
JMPWA
114
JP Morgan Private Wealth Advisors
California
$15M -$570K -28,374 -4%
Susquehanna International Group
115
Susquehanna International Group
Pennsylvania
$15M +$293K +14,604 +2%
VRS
116
Virginia Retirement Systems
Virginia
$14.9M -$1.99M -98,928 -12%
PPA
117
Parametric Portfolio Associates
Washington
$13.7M +$2.12M +105,444 +20%
AAM
118
Aberdeen Asset Management
United Kingdom
$13.6M +$7.61M +378,624 +144%
EAM
119
Edge Asset Management
Washington
$13.5M +$378K +18,822 +3%
PI
120
PGGM Investments
Netherlands
$13.4M -$546K -27,174 -4%
DL
121
Delta Lloyd
Netherlands
$13.2M -$289K -14,388 -2%
PI
122
PineBridge Investments
New York
$13.1M +$5.39M +268,524 +77%
OAM
123
Oxford Asset Management
United Kingdom
$13M -$1.78M -88,500 -13%
HSBC Holdings
124
HSBC Holdings
United Kingdom
$12.9M +$1.66M +82,626 +16%
BA
125
Broadview Advisors
Wisconsin
$12.9M -$4.04M -201,300 -25%

EW Hedge Fund Activity: Q4 2014 in Review

556 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q4 2014, worth a combined $11.7B — down 5.3% from $12.4B a quarter earlier.

Buyers outnumbered sellers: 97 funds opened new EW positions and 31 closed out — a net gain of 66 holders — while 193 added to existing stakes and 182 trimmed.

The largest buyer was AQR Capital Management, adding an estimated $85M. The largest seller was Capital Research Global Investors, cutting an estimated $232M.

  • 556 institutional investors held Edwards Lifesciences (EW) as of Q4 2014, up from 496 in Q3 2014.
  • Funds reported $11.7B of Edwards Lifesciences stock for Q4 2014, down 5.3% quarter-over-quarter.
  • 97 funds opened new Edwards Lifesciences positions in Q4 2014 and 31 closed out, a net change of +66 holders.
  • The largest Edwards Lifesciences buyer in Q4 2014 was AQR Capital Management, an estimated $85M added.
  • The largest Edwards Lifesciences seller in Q4 2014 was Capital Research Global Investors, an estimated $232M sold.

Based on aggregated 13F filings for Q4 2014.